Tesamorelin/ipamorelin blend overview covering GH-axis mechanisms, authorized tesamorelin evidence, missing blend trials, safety and COA verification.
This blend combines tesamorelin, a GHRH analogue, with ipamorelin, a ghrelin-receptor agonist. Both act upstream of growth-hormone release through different receptors.
An authorized tesamorelin product has evidence for a narrow indication. That does not validate Quantum’s mixture, extend the indication or establish the effects of adding ipamorelin.
Mechanism explains why a compound enters a research conversation. It does not establish that the compound is effective, appropriate or safe for a person.
Tesamorelin stimulates the GHRH receptor; ipamorelin engages the growth-hormone secretagogue receptor. The proposed blend rationale is convergent GH/IGF-1-axis signalling.
Convergence does not prove synergy. IGF-1 response, glucose effects, edema and pituitary feedback can vary, and no direct trial defines the 32 mg + 8 mg formulation.
These are recurring questions in the published literature. They are research themes, not promised outcomes or personal recommendations.
Clinically proven ~15-20% reduction in visceral adipose tissue (VAT) over 26 weeks
Significant reductions in triglycerides and improved cholesterol ratios
Lean body mass preservation
Potential cognitive benefits via IGF-1-mediated neuroprotection, with exploratory data in NAFLD and metabolic syndrome
Selective GH stimulation with no meaningful cortisol or stress-hormone spike
Increased lean muscle mass and reduction in abdominal body fat
Randomized tesamorelin trials studied a defined prescription product in HIV-associated abdominal-fat populations. Ipamorelin has separate early pharmacokinetic research.
What the evidence cannot answer: Neither evidence base studies this exact combination. It is inaccurate to treat the blend as an approved “performance” or generalized fat-loss product.
Open the published batch report and match its COA number to the vial used in your research.
View Tesamorelin + Ipamorelin COAResearch-market naming does not establish identity, concentration or purity. A useful certificate of analysis identifies the batch, analytical method and measured result. Match the COA number to the vial rather than relying on a site-wide percentage or a study of a different product.
Independent verification: every certificate of analysis carries a code you can check yourself at Peptide Test Canada, an independent third-party testing lab — you don't have to take our word for it.
Quantum publishes an individual report for this entry and keeps the broader lab-results archive available for comparison.
GH-axis review includes malignancy, pituitary disease, glucose regulation, edema, sleep apnea, pregnancy and IGF-1 interpretation.
Product status: Authorized tesamorelin evidence is product- and indication-specific. Quantum’s combined RUO vial is not represented as that prescription medicine.
The tracker organizes cycle boundaries, injection timing, body-composition measurements, training recovery and clinician-directed IGF-1 or glucose review.
Cadence, timing and cycle are owner-draft previews. Dose, dilution, titration, inventory, check-ins and change history remain inside the tracker after purchase.
Concise answers that keep mechanism, evidence, product quality and regulatory status separate.
This blend combines tesamorelin, a GHRH analogue, with ipamorelin, a ghrelin-receptor agonist. Both act upstream of growth-hormone release through different receptors.
Tesamorelin stimulates the GHRH receptor; ipamorelin engages the growth-hormone secretagogue receptor. The proposed blend rationale is convergent GH/IGF-1-axis signalling.
Randomized tesamorelin trials studied a defined prescription product in HIV-associated abdominal-fat populations. Ipamorelin has separate early pharmacokinetic research. Blend-specific pharmacokinetics, interaction effects, titration, efficacy and long-term safety are not established.
Authorized tesamorelin evidence is product- and indication-specific. Quantum’s combined RUO vial is not represented as that prescription medicine.
This educational page does not provide a protocol. Published exposure, when available, is specific to the studied or authorized product and cannot be transferred to Quantum’s research-use-only material. Use the tracker only as an organizational record, not a substitute for qualified medical care.
Use the individual batch report to verify identity, analytical method, reported purity and COA number. Match that number to the vial; a general purity claim is not batch verification.